At a glance
ClinicalIndex Comparison RecordN/ACompleted· 55 enrolled
Drug / intervention
topical brimonidine tartrate 0.15% (Alphagan® P; Allergan, Inc)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Hypotensive Efficacy of Topical Prophylaxis for Intraocular Pressure Spikes Following Intravitreal Injections of Anti-vascular Endothelial Growth Factor Agents
In Brief
A clinical study evaluating topical brimonidine tartrate 0.15% (Alphagan® P; Allergan, Inc) for Post-Injection Intraocular Pressure Spikes. Completed, enrolled 55 participants.
Detailed Summary
In this study, investigators will be examining the intraocular pressure lowering effect of brimonidine 0.15% when administered 20min prior to intravitreal anti-VEGF injection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
CollaboratorsDr. Efrem Mandelcorn
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartDec 2016
Primary CompletionJul 2017
Study CompletionSep 2017
First PostedMay 2018
TodayJul 2026
First PostedMay 1, 2018
Enrollment StartDec 15, 2016
Primary CompletionJul 15, 2017
Study CompletionSep 1, 2017
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 8.2 years ago
Interventions
topical brimonidine tartrate 0.15% (Alphagan® P; Allergan, Inc)drug
The rapid hypotensive effects of topical alpha2-agonists such as brimonidine tartrate on decreasing aqueous production and increasing uveoscleral outflow, in addition to their neuroprotective properties, make them an attractive option for prophylactic treatment of post-injection IOP spikes.